Syros to Participate in JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced its participation at the JMP Securities Life Sciences Conference, including in a panel discussion, as follows:

JMP Securities Life Sciences ConferenceDate: Tuesday, June 20Panel Title: Epigentics and Transcriptional Control – Regulating the RegulatorsPanel Time: 11:00-11:55 a.m. ETLocation: The St. Regis New York, 2 East 55 Street, New York, NY

About Syros PharmaceuticalsSyros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170613006322/en/

Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
[email protected]
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
[email protected]

Source: Syros Pharmaceuticals

You May Also Be Interested In

• Beyond the Credential: As AI Erases the 'Entry-Level Job' and Climate Volatility Accelerates, Planet Classroom Unveils July Lineup Mapping the New Rules of Human Resilience
• MEDIA ADVISORY - Championship Game to Crown the 37th Annual Brick Invitational Hockey Tournament Champions
• 5 Best Crypto Presales as Bitcoin Whales Buy $16.7B and Retail Looks for the Next Early Entry